Detection of Prostate Cancer and Predicting Progression

Carcinoma of the prostate is the second leading cause of male cancer-related death in the United States. Better indicators of prostate cancer presence and progression are needed to avoid unnecessary treatment, predict disease course, and develop more effective therapy. Numerous molecular markers have been described in human serum, urine, seminal fluid, and histological specimens that exhibit varying capacities to detect prostate cancer and predict disease course. However, to date, few of these markers have been adequately validated for clinical use. The purpose of this review is to examine the current status of these markers in prostate cancer and to assess the diagnostic potential for future markers from identified genes and molecules that display loss, mutation, or alteration in expression between tumor and normal prostate tissues. In this review we cite 91 molecular markers that display some level of correlation with prostate cancer presence, disease progression, cancer recurrence, prediction of response to therapy, and/or disease-free survival. We suggest criteria to consider when selecting a marker for further development as a clinical tool and discuss five examples of markers (chromogranin A, glutathione S-transferase π 1, prostate stem cell antigen, prostate-specific membrane antigen, and telomerase reverse transcriptase) that fulfill some of these criteria. Finally, we discuss how to conduct evaluations of candidate prostate cancer markers and some of the issues involved in the validation process.

[1]  J. Richie,et al.  Expression of telomerase subunits in normal and neoplastic prostate epithelial cells isolated by laser capture microdissection , 2001, Cancer.

[2]  L. Dogliotti,et al.  Circulating neuroendocrine markers in patients with prostate carcinoma , 2000, Cancer.

[3]  P. Schellhammer,et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.

[4]  M. Oshimura,et al.  Detection of telomerase activity in prostate cancer by needle biopsy. , 1997, European urology.

[5]  G. Chatta.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer , 2003 .

[6]  T. Stamey,et al.  Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. , 1998, The Journal of urology.

[7]  M. Loda,et al.  Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer , 2000, Oncogene.

[8]  L. Klotz,et al.  Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. , 1998, Cancer research.

[9]  D. Sidransky,et al.  Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. , 2001, Journal of the National Cancer Institute.

[10]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[11]  D. S. Coffey,et al.  Telomerase activity: a prevalent marker of malignant human prostate tissue. , 1996, Cancer research.

[12]  H. Ragde,et al.  Presentation of prostate tumor antigens by dendritic cells stimulates T‐cell proliferation and cytotoxicity , 1996, The Prostate.

[13]  A. Gutman,et al.  Theory and Application of the Serum “acid” Phosphatase Determination in Metastasizing Prostatic Carcinoma; Early Effects Of Castration , 1942 .

[14]  P. Guinan,et al.  An evaluation of prostate specific antigen in prostatic cancer. , 1987, The Journal of urology.

[15]  J. Brooks,et al.  Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. Piantadosi,et al.  Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. , 2001, Cancer research.

[17]  J. Mccormick,et al.  Cloning and characterization of a novel gene encoding a putative transmembrane protein with altered expression in some human transformed and tumor-derived cell lines , 1999, Oncogene.

[18]  A. Uchida,et al.  Prostate‐specific suicide gene therapy using the prostate‐specific membrane antigen promoter and enhancer , 2000, The Prostate.

[19]  M. Hara,et al.  [Some physico-chemical characteristics of " -seminoprotein", an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII]. , 1971, Nihon hoigaku zasshi = The Japanese journal of legal medicine.

[20]  V. Paradis,et al.  Expression of the RNA component of human telomerase (hTR) in prostate cancer, prostatic intraepithelial neoplasia, and normal prostate tissue , 1999, The Journal of pathology.

[21]  D. Bostwick,et al.  Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma , 1998, Cancer.

[22]  J. Cheville,et al.  Metastatic prostate carcinoma to bone , 2002, Cancer.

[23]  D. G. Altman,et al.  Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.

[24]  K. Tsao,et al.  Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy , 1999, Journal of clinical laboratory analysis.

[25]  A. Rademaker,et al.  Re: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. , 1990, The Journal of urology.

[26]  A. Pecking,et al.  Serum chromogranin‐A in advanced prostate cancer , 2001, BJU international.

[27]  M. Hosaka,et al.  Telomerase activity in primary prostate cancer. , 1997, The Journal of urology.

[28]  A. Partin,et al.  Comparison of serum PSMA, PSA levels with results of cytogen‐356 ProstaScint® scanning in prostatic cancer patients , 1997, The Prostate.

[29]  K. Klinger,et al.  Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 , 2002, Nature Genetics.

[30]  George D. Lundberg.  Gradwohl's Clinical Laboratory Methods and Diagnosis: , 1972 .

[31]  K. Ohyashiki,et al.  A combination of semiquantative telomerase assay and in‐cell telomerase activity measurement using exfoliated urothelial cells for the detection of urothelial neoplasia , 1998, Cancer.

[32]  N. Bander,et al.  Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line , 2003, The Prostate.

[33]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  Z. Hall.  Cancer , 1906, The Hospital.

[35]  M. Rubin,et al.  Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. , 2002, Cancer research.

[36]  John D Minna,et al.  Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  B. Wullich,et al.  Focal intratumoral heterogeneity for telomerase activity in human prostate cancer. , 1999, The Journal of urology.

[38]  J. Brooks,et al.  GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. , 2001, The American journal of pathology.

[39]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[40]  J. Grayhack,et al.  Biochemical markers in prostatic cancer. , 1984, The Urologic clinics of North America.

[41]  J. Shay,et al.  Telomere shortening may contribute to aging and cancer: A perspective , 1994 .

[42]  M. Hammond,et al.  Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. , 2002, Seminars in oncology.

[43]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[44]  W. Baum,et al.  Serum phosphatase determinations in diagnosis of prostatic cancer; a review of 1,150 cases. , 1951, Journal of the American Medical Association.

[45]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[46]  C. Wadelius,et al.  Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. , 1999, Pharmacogenetics.

[47]  K. Miller,et al.  DNA-based detection of prostate cancer in urine after prostatic massage. , 2001, Urology.

[48]  C. Moskaluk,et al.  Immunohistochemical expression of π‐class glutathione S‐transferase is down‐regulated in adenocarcinoma of the prostate , 1997, Cancer.

[49]  A. Vlahou,et al.  Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  D. Sidransky,et al.  I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[51]  O. Cussenot,et al.  htert expression correlates with MYC over‐expression in human prostate cancer , 2000, International journal of cancer.

[52]  M. Marberger,et al.  Polymorphisms of glutathione‐S‐transferase genes (GSTP1, GSTM1 and GSTT1) and prostate‐cancer risk , 2001, International journal of cancer.

[53]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[54]  R. Hubert,et al.  Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[55]  S. Gelmini,et al.  Telomerase in urological malignancy. , 2001, The Journal of urology.

[56]  R. B. H. Gradwohl,et al.  Gradwohl's Clinical Laboratory Methods and Diagnosis , 1980 .

[57]  J. Hugosson,et al.  Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. , 2000, Urology.

[58]  W. Schulz,et al.  Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma , 2000, Archives of Toxicology.

[59]  A. D. Smith,et al.  Secretion of a Chromaffin Granule Protein, Chromogranin, from the Adrenal Gland after Splanchnic Stimulation , 1967, Nature.

[60]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[61]  A. Ferrando,et al.  Prostate-specific membrane antigen in breast carcinoma , 1997, The Lancet.

[62]  J. Herman,et al.  Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[63]  H. Klocker,et al.  Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. , 1998, Urology.

[64]  T. Stamey,et al.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. , 1988, The New England journal of medicine.

[65]  R. Beltz,et al.  Telomerase activity in prostate sextant needle cores from radical prostatectomy specimens. , 2001, Urologic oncology.

[66]  R. Eeles,et al.  Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. , 2001, Pharmacogenetics.

[67]  V. Srikantan,et al.  HEPSIN inhibits cell growth/invasion in prostate cancer cells. , 2002, Cancer research.

[68]  S. Lightman,et al.  Endogenous Neurotensin Regulates Hypothalamic‐Pituitary‐Adrenal Axis Activity and Peptidergic Neurons in the Rat Hypothalamic Paraventricular Nucleus , 1997, Journal of neuroendocrinology.

[69]  G. Murphy,et al.  Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. , 1995, Anticancer research.

[70]  J. Brooks,et al.  CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[71]  M. Tarle,et al.  Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients. , 2001, Anticancer research.

[72]  E. Cooper.  Clinical Utility of Prostate Specific Antigen in the Management of Prostatic Cancer , 1988 .

[73]  P. Schellhammer,et al.  Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. , 2001, Cancer research.

[74]  R. Moyzis,et al.  Association between outcome and telomere DNA content in prostate cancer. , 1999, The Journal of urology.

[75]  D. Sidransky,et al.  Absence of ST7 gene alterations in human cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[76]  Jeffrey A. Magee,et al.  Expression profiling reveals hepsin overexpression in prostate cancer. , 2001, Cancer research.

[77]  D. Aunis,et al.  Biochemistry of the chromogranin A protein family. , 1989, The Biochemical journal.

[78]  M. Astill,et al.  Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patients , 1998, Journal of clinical laboratory analysis.

[79]  J. Womersley,et al.  Measurement of the W boson mass at the LHC , 1997, hep-ph/9711304.

[80]  E. Sproul,et al.  Significance of Increased Phosphatase Activity of Bone at the Site of Osteoplastic Metastases Secondary to Carcinoma of the Prostate Gland , 1936 .

[81]  P. Walsh,et al.  RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. , 2003, The Journal of urology.

[82]  A. Lu,et al.  Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. , 2002, The Journal of urology.

[83]  M. Loda,et al.  Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[84]  S. Clark,et al.  Detailed methylation analysis of the glutathione S-transferase π (GSTP1) gene in prostate cancer , 1999, Oncogene.

[85]  M. Groettrup,et al.  Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. , 2000, Cancer research.

[86]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[87]  A. Brothman.  Cytogenetics and molecular genetics of cancer of the prostate. , 2002, American journal of medical genetics.

[88]  J. Ross,et al.  Telomerase Activity in Human Benign Prostate Tissue and Prostatic Adenocarcinomas , 1997, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[89]  Arul M Chinnaiyan,et al.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. , 2003, Journal of the National Cancer Institute.

[90]  A. Foti,et al.  Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase. , 1977, The New England journal of medicine.

[91]  P. Riegman,et al.  The prostate‐specific antigen gene and the human glandular kallikrein‐1 gene are tandemly located on chromosome 19 , 1989, FEBS letters.

[92]  K. Jegatheesan,et al.  A METHOD FOR THE DETERMINATION OF TARTRATE-LABILE, PROSTATIC ACID PHOSPHATASE IN SERUM , 1959, Journal of clinical pathology.

[93]  S. Takeha,et al.  Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. , 1997, The Journal of urology.

[94]  K. Tsao,et al.  Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages. , 2000, Annals of clinical and laboratory science.

[95]  J. Goméz,et al.  Serum prostate specific antigen as pre-screening test for prostate cancer. , 1992, The Journal of urology.

[96]  G. Murphy,et al.  Measurement of prostate‐specific membrane antigen in the serum with a new antibody , 1996, The Prostate.

[97]  J. Minna,et al.  Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. , 2001, Cancer research.

[98]  T. Y. Wang,et al.  Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer. , 1986, Annals of clinical and laboratory science.

[99]  E. Green,et al.  Mutational and functional analyses reveal that ST7 is a highly conserved tumor-suppressor gene on human chromosome 7q31 , 2001, Nature Genetics.

[100]  J. Hayes,et al.  The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. , 1995, Critical reviews in biochemistry and molecular biology.

[101]  S. Fosså,et al.  Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer , 2001, The Prostate.

[102]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[103]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[104]  J. Moul,et al.  Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients , 1997, Cancer.

[105]  M. Pavone-Macaluso,et al.  An appraisal of telomerase activity in benign prostatic hyperplasia , 2000, The Prostate.

[106]  Q. Ding,et al.  [Detection of telomerase activity in prostate needle-biopsy samples]. , 1999, Zhonghua wai ke za zhi [Chinese journal of surgery].

[107]  R. Reiter,et al.  Role of prostate stem cell antigen in prostate cancer research , 2002, Current opinion in urology.

[108]  W. Cooner,et al.  Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. , 1990, The Journal of urology.

[109]  F. Bosman,et al.  The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage. , 2001, The Journal of urology.

[110]  S. Cappia,et al.  Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[111]  P. di Sant'Agnese,et al.  Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. , 1996, Urology.

[112]  D. Bostwick,et al.  Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.

[113]  R. Lamerz,et al.  Screening for prostatic carcinoma with prostate specific antigen. , 1997, Anticancer research.

[114]  V. Reuter,et al.  Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. , 1997, The Journal of urology.

[115]  M. Diaz,et al.  Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN). , 1998, The Journal of urology.

[116]  S. Venitt,et al.  Detection of telomerase activity in human prostate: a diagnostic marker for prostatic cancer? , 1997, British journal of urology.

[117]  G. Murphy,et al.  A prostate antigen in sera of prostatic cancer patients. , 1980, Cancer research.

[118]  T. Beaty,et al.  Transmission/disequilibrium tests of androgen receptor and glutathione S‐transferase pi variants in prostate cancer families , 2002, International Journal of Cancer.

[119]  P. Chieco,et al.  Telomerase Activity in Touch–Imprint Cell Preparations from Fresh Prostate Needle Biopsy Specimens , 2001, European Urology.

[120]  V. Bilim,et al.  Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[121]  Herbert,et al.  Detection of telomerase activity in prostatic fluid specimens. , 2000, Urologic oncology.

[122]  M. Loda,et al.  Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer , 2000, Genes, chromosomes & cancer.

[123]  L. Dogliotti,et al.  Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[124]  George L. Wright,et al.  Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids , 1995, International journal of cancer.

[125]  K. Akakura,et al.  Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. , 2002, The Journal of urology.

[126]  B. Suffoletto,et al.  Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[127]  W. Fair,et al.  Expression of the prostate-specific membrane antigen. , 1994, Cancer research.

[128]  W. Isaacs,et al.  CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[129]  K. Tsao,et al.  Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[130]  C. Tseng,et al.  The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma. , 2002, The Journal of urology.

[131]  G. Murphy,et al.  Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. , 1987, Anticancer research.

[132]  A. Gutman,et al.  AN " ACID " PHOSPHATASE OCCURRING IN THE SERUM OF PATIENTS WITH METASTASIZING CARCINOMA OF THE PROSTATE GLAND. , 1938, The Journal of clinical investigation.

[133]  L. Deftos,et al.  Granins and prostate cancer. , 1998, Urology.